A liquid biopsy is a minimally invasive medical test used to diagnose and track diseases like cancer by finding biomarkers in a patient’s blood or other bodily fluids like saliva or urine. Liquid biopsies use sophisticated molecular biology techniques to capture and study circulating tumour cells (CTCs), cell-free DNA (cfDNA), and other biomolecules found in bodily fluids, in contrast to standard biopsies, which involve an invasive surgical procedure to obtain tissue samples.
According to SPER market research, ‘Middle East Liquid Biopsy Market Size- By Technology, By Work Flow, By Usage, By Sample, By Circulating Biomarker, By Product- Regional Outlook, Competitive Strategies and Segment Forecast to 2033’ state that the Middle East Liquid Biopsy Market is predicted to reach USD 0.208 billion by 2033 with a CAGR 13.89%.
Liquid biopsy is an innovative medical technique for detecting and monitoring diseases, particularly cancer, without the need for invasive tissue extraction. It utilizes advancements in human genome sequencing and sensitive detection methods. Unlike traditional biopsies, liquid biopsy uses easily accessible samples like blood and urine, minimizing patient discomfort. It serves as a valuable alternative for individuals unable to undergo risky tissue biopsies, enhancing patient comfort and safety, especially in cases like lung cancer near vital organs.
The increasing investment from the federal government is anticipated to propel the market’s growth rate. The market will gain from research operations that ensure a high return on investment. The market growth rate is positively impacted by government awareness-raising campaigns, especially in developing nations; rising personal disposable income; the introduction of technologically advanced products in hospitals; increased investment in the development of cutting-edge medical products and devices; and rising demand for non-invasive surgical procedures. Growing R&D spending is anticipated to create even more profitable market expansion potential for medical devices and equipment, especially in developed and developing nations. The research and development capacities of pharmaceutical and biopharmaceutical nations for the integration of state-of-the-art technology in healthcare facilities are also driving the market growth rate.
It is anticipated that the low sensitivity of some liquid biopsies, restricted infrastructure, and high expenses related to R&D capabilities will hinder market expansion. The low sensitivity and specificity limitations of liquid biopsy, the lack of appropriate infrastructure in low- and middle-income countries, the requirement for significant capital investments to set up production facilities, the absence of favourable reimbursement scenarios and technology penetration in developing economies, and other factors are anticipated to present challenges to the market during the forecast period.
Request For Free Sample Report @ https://www.sperresearch.com/report-store/middle-east-liquid-biopsy-market.aspx?sample=1
Impact of COVID-19 on Middle East Liquid Biopsy Market
The COVID-19 pandemic had a significant impact on revenue growth and market share. Due to lower demand, manufacturers first suffered losses; however, the second half of 2021 experienced a compensatory increase. However, it is expected that the industry will have significant effects between 2020 and 2022. A notable factor affecting Exact Sciences’ Cologuard test sales during the pandemic was a decrease in the number of cancer patients in hospitals and diagnostic labs.
Middle East Liquid Biopsy Market Key Players:
Additionally, some of the market key players are Bio-Rad Laboratories, Inc., Bioscience Institute S.p.A., Eurofins Scientific, F. Hoffmann-La Roche Ltd, and others.
MENA Liquid Biopsy Market Segmentation:
The SPER Market Research report seeks to give market dynamics, demand, and supply forecasts for the years up to 2033. This report contains statistics on product type segment growth estimates and forecasts.
By Technology: Based on the Technology, Middle East Liquid Biopsy Market is segmented as; Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ Hybridization, Other Technologies.
By Work Flow: Based on the Work Flow, Middle East Liquid Biopsy Market is segmented as; Sample Preparation, Library Preparation, Sequencing, Data Analysis.
By Usage: Based on the Usage, Middle East Liquid Biopsy Market is segmented as; Research Use Only, Clinical.
By Sample: Based on the Sample, Middle East Liquid Biopsy Market is segmented as; Blood, Urine, Saliva.
By Circulating Biomarker: Based on Circulating Biomarker, Middle East Liquid Biopsy Market is segmented as; Circulating Tumor Cells, Cell-Free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles, Other Circulating Biomarkers.
By Product: Based on the Product, Middle East Liquid Biopsy Market is segmented as; Tests/Services, Kits and Consumables, Instruments.
By Region: This report also provides the data for key regional segments of Europe; Kingdom of Saudi Arabia, United Arab Emirates, Rest of Middle East.
This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.
For More Information, refer to below link:-
MENA Liquid Biopsy Market Revenue
Related Reports:
Follow Us –
LinkedIn | Instagram | Facebook | Twitter
Contact Us:
Sara Lopes, Business Consultant – U.S.A.
SPER Market Research
+1-347-460-2899
